GenEdit
Healthcare & Life Sci
Company overview
BreezeBio develops genetic medicines that deliver treatment directly to specific cells and tissues, with a focus on autoimmune diseases. NanoGalaxy is its programmable platform for delivering genetic payloads. Its lead program, BRZ-101, is a therapy for Type 1 Diabetes designed to induce immune tolerance.
BreezeBio was co-founded by Kunwoo (Ryan) Lee, Hyo Min (Huey) Park, and Niren Murthy. Its investors include Eli Lilly and Sequoia. GenEdit is an H-1B sponsor.
- Industry
- Healthcare & Life Sci
- Headquarters
- Brisbane, United States